SCHEMBL25568264

SCHEMBL25568264

COC(=O)C1(CN)CC(N(Cc2ccccc2)Cc2ccccc2)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
MAPT P10636 2/20 0.39
CCR5 P51681 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
TSHR P16473 3/20 0.37
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CYP3A4 P08684 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
DPP8 Q6V1X1 1/20 0.36
DPP7 Q9UHL4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25568267 0.88 MAPT (0.42) MAPTCCR5NPC1RAB9ATSHR
SCHEMBL25568266 0.88 MAPT (0.40) SLC6A2SLC6A4MAPTCCR5NPC1
SCHEMBL25568263 0.88 MAPT (0.40) SLC6A2SLC6A4MAPTCCR5NPC1
SCHEMBL25568262 0.88 MAPT (0.40) SLC6A2SLC6A4MAPTCCR5NPC1
SCHEMBL25573149 0.84 CCR5 (0.37) MAPTCCR5NPC1RAB9ATSHR
SCHEMBL25573147 0.84 CCR5 (0.37) MAPTCCR5NPC1RAB9ATSHR
SCHEMBL20690478 0.82 CCR5 (0.43) MAPTCCR5NPC1RAB9ATSHR
SCHEMBL25568265 0.81 MYC (0.38) MAPTCCR5NPC1RAB9ATSHR
SCHEMBL25572909 0.80 MAPT (0.37) MAPTCCR5TSHRALDH1A1SMN1; SMN2
SCHEMBL25699122 0.80 MAPT (0.37) MAPTCCR5TSHRALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023091438-A1 CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS MERCK SHARP & DOHME LLC (US) 2023-05-25 WO disclosed
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2023-05-25 US disclosed
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS TCOF1, SLC10A2, PAM SLC6A2 981/4885SLC6A4 2906/4885MAPT 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.